20/20 Biolabs, Inc.
AIDX
$0.53
$0.012.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.74% | -66.29% | -58.43% | 1.83% | -9.98% |
| Total Depreciation and Amortization | 10.61% | -10.95% | -4.74% | 0.00% | -10.21% |
| Total Amortization of Deferred Charges | 14.48% | 145.56% | 469.19% | -- | -- |
| Total Other Non-Cash Items | -35.43% | 74.97% | 211.42% | 0.00% | 0.00% |
| Change in Net Operating Assets | 326.71% | -124.61% | 2.26% | 73.40% | 26.32% |
| Cash from Operations | 53.03% | -151.91% | -32.67% | 27.79% | -9.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -38.89% | -- | -- | -- | -- |
| Cash from Investing | -38.89% | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -39.31% | -18.69% | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -80.00% | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 92.13% | -3,090.79% | -- | -- | -- |
| Cash from Financing | -79.05% | 1,042.41% | -22.46% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.76% | 2,785.53% | -198.35% | 122.64% | -136.33% |